The effects of activated charcoal on digoxin and digitoxin clearance

The effect of multiple oral doses of activated charcoal on digitalis glycoside kinetics was studied to determine whether an activated charcoal regimen might have utility in treating patients with digitalis toxicity. Normal subjects were given intravenous infusions of digoxin 0.75 mg/70 kg or digitox...

Full description

Saved in:
Bibliographic Details
Published inDrug intelligence & clinical pharmacy Vol. 19; no. 12; p. 937
Main Authors Park, G D, Goldberg, M J, Spector, R, Johnson, G F, Feldman, R D, Quee, C K, Roberts, P
Format Journal Article
LanguageEnglish
Published United States 01.12.1985
Subjects
Online AccessGet more information
ISSN0012-6578
DOI10.1177/106002808501901216

Cover

Abstract The effect of multiple oral doses of activated charcoal on digitalis glycoside kinetics was studied to determine whether an activated charcoal regimen might have utility in treating patients with digitalis toxicity. Normal subjects were given intravenous infusions of digoxin 0.75 mg/70 kg or digitoxin 1 mg/70 kg iv followed by either water alone or water with activated charcoal in divided doses in a randomized crossover design. A subject with chronic renal failure was also given digoxin 0.5 mg/70 kg iv followed by water alone or water with activated charcoal. In six normal subjects, treatment with activated charcoal did not increase digoxin clearance (Cl) significantly (16.79 +/- 1.70 vs. 22.68 +/- 3.51 L/h). However, digitoxin Cl did increase significantly, from 0.24 +/- 0.01 to 0.47 +/- 0.04 L/h. In the renal failure subject, digoxin Cl increased from 3.6 L/h to 10.1 L/h. We conclude that the activated charcoal regimen is probably useful in patients with digitoxin toxicity. Although similar benefit is limited in patients with normal renal function who develop digoxin toxicity, it is possible that activated charcoal will be useful in patients with prolonged digoxin elimination due to renal dysfunction.
AbstractList The effect of multiple oral doses of activated charcoal on digitalis glycoside kinetics was studied to determine whether an activated charcoal regimen might have utility in treating patients with digitalis toxicity. Normal subjects were given intravenous infusions of digoxin 0.75 mg/70 kg or digitoxin 1 mg/70 kg iv followed by either water alone or water with activated charcoal in divided doses in a randomized crossover design. A subject with chronic renal failure was also given digoxin 0.5 mg/70 kg iv followed by water alone or water with activated charcoal. In six normal subjects, treatment with activated charcoal did not increase digoxin clearance (Cl) significantly (16.79 +/- 1.70 vs. 22.68 +/- 3.51 L/h). However, digitoxin Cl did increase significantly, from 0.24 +/- 0.01 to 0.47 +/- 0.04 L/h. In the renal failure subject, digoxin Cl increased from 3.6 L/h to 10.1 L/h. We conclude that the activated charcoal regimen is probably useful in patients with digitoxin toxicity. Although similar benefit is limited in patients with normal renal function who develop digoxin toxicity, it is possible that activated charcoal will be useful in patients with prolonged digoxin elimination due to renal dysfunction.
Author Park, G D
Spector, R
Roberts, P
Goldberg, M J
Feldman, R D
Quee, C K
Johnson, G F
Author_xml – sequence: 1
  givenname: G D
  surname: Park
  fullname: Park, G D
– sequence: 2
  givenname: M J
  surname: Goldberg
  fullname: Goldberg, M J
– sequence: 3
  givenname: R
  surname: Spector
  fullname: Spector, R
– sequence: 4
  givenname: G F
  surname: Johnson
  fullname: Johnson, G F
– sequence: 5
  givenname: R D
  surname: Feldman
  fullname: Feldman, R D
– sequence: 6
  givenname: C K
  surname: Quee
  fullname: Quee, C K
– sequence: 7
  givenname: P
  surname: Roberts
  fullname: Roberts, P
BackLink https://www.ncbi.nlm.nih.gov/pubmed/4085353$$D View this record in MEDLINE/PubMed
BookMark eNotj8FKAzEURbOo1Lb6A4KQHxh9SSbJ61KqVqHgpq7Lm-TFjkwzZWYU_XtH7eqeC4cLdy4muc0sxJWCG6W8v1XgADQCWlBLUFq5iZjBCIWzHs_FvO_fAQwsnZuKaTl6xpqZuN_uWXJKHIZetklSGOpPGjjKsKcutNTINstYv7VfdZaU4y_Xw18LDVNHOfCFOEvU9Hx5yoV4fXzYrp6Kzcv6eXW3KYJxy6GIFSSLZCrLqsTkWJOyAVlb1BFT8FiZCpR36EeJokeMqDQmr5MpbdILcf2_e_yoDhx3x64-UPe9O73RPzc2TB0
CitedBy_id crossref_primary_10_1053_ajkd_2000_8291
crossref_primary_10_1081_CLT_100102451
crossref_primary_10_2165_00129784_200606020_00002
crossref_primary_10_1177_0310057X9001800315
crossref_primary_10_3109_15563659409011043
crossref_primary_10_2165_00003088_200746110_00001
crossref_primary_10_2165_00042310_200723020_00007
crossref_primary_10_1111_j_1365_2710_1993_tb00564_x
crossref_primary_10_1016_S1164_6756_05_80006_4
crossref_primary_10_1016_S0196_0644_89_80116_7
crossref_primary_10_1080_15563650_2021_1961144
crossref_primary_10_1111_j_1600_0773_1993_tb01644_x
crossref_primary_10_1016_S0749_0704_18_30471_8
crossref_primary_10_5694_j_1326_5377_1990_tb124464_x
crossref_primary_10_1016_S0196_0644_95_70295_4
crossref_primary_10_1111_j_1365_2125_2012_04449_x
crossref_primary_10_1111_bcp_12814
crossref_primary_10_1016_0735_6757_91_90162_D
crossref_primary_10_1097_FTD_0b013e31802bfd69
crossref_primary_10_1016_0735_6757_92_90210_O
crossref_primary_10_1097_MAJ_0b013e318176b94d
crossref_primary_10_1016_S0196_0644_05_81608_7
crossref_primary_10_1111_bcpt_13553
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1177/106002808501901216
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 4085353
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, U.S. Gov't, P.H.S
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NCRR NIH HHS
  grantid: RR00059
– fundername: NCRR NIH HHS
  grantid: RR 07035-16
GroupedDBID .GJ
41~
53G
5RE
AACKU
AAGGD
AAJIQ
AAJOX
AANSI
AAPEO
AAQXH
AARDL
AAWTL
AAXOT
AAYTG
AAZBJ
ABDWY
ABHKI
ABJNI
ABPGX
ABQKF
ABVVC
ABYTW
ACFMA
ACFYK
ACGBL
ACGFS
ACLHI
ADEIA
ADMPF
ADNBR
ADTBJ
ADUKL
AECVZ
AEWDL
AEXFG
AFFNX
AFKBI
AIGRN
AJABX
AJEFB
AJMMQ
AJSCY
ALMA_UNASSIGNED_HOLDINGS
CBRKF
CGR
CORYS
CQQTX
CUTAK
CUY
CVF
DC0
DD-
DD0
DE-
DE.
DN0
ECM
EIF
F5P
NPM
Q1R
ROL
SAUOL
SCNPE
SFC
ZGI
ID FETCH-LOGICAL-c369t-db0f58a3b5e148f6e2a15c8e2582d8fc78b3b017687a3bad788d8128f72f345f2
ISSN 0012-6578
IngestDate Wed Feb 19 02:35:49 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c369t-db0f58a3b5e148f6e2a15c8e2582d8fc78b3b017687a3bad788d8128f72f345f2
PMID 4085353
ParticipantIDs pubmed_primary_4085353
PublicationCentury 1900
PublicationDate 19851200
PublicationDateYYYYMMDD 1985-12-01
PublicationDate_xml – month: 12
  year: 1985
  text: 19851200
PublicationDecade 1980
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Drug intelligence & clinical pharmacy
PublicationTitleAlternate Drug Intell Clin Pharm
PublicationYear 1985
SSID ssj0030966
Score 1.3862648
Snippet The effect of multiple oral doses of activated charcoal on digitalis glycoside kinetics was studied to determine whether an activated charcoal regimen might...
SourceID pubmed
SourceType Index Database
StartPage 937
SubjectTerms Adult
Charcoal - therapeutic use
Digitoxin - adverse effects
Digitoxin - metabolism
Digoxin - adverse effects
Digoxin - metabolism
Humans
Kidney Failure, Chronic - metabolism
Kidney Failure, Chronic - therapy
Kinetics
Male
Title The effects of activated charcoal on digoxin and digitoxin clearance
URI https://www.ncbi.nlm.nih.gov/pubmed/4085353
Volume 19
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8QwFA4uCF7EFXdyEC9amabN0qM4LgjKHEbwJk2TiKDtoKOov96XJpOWcUG9lE4yhJl-X17fS973gtCO6aRaZSyPYq7TKNUdmFKa2RyxJBcmNx3FrHb44pKdXaXn1_S62cGv1SVDeVC8f6kr-Q-q0Aa4WpXsH5ANg0ID3AO-cAWE4fprjFsJGVaj8JJbF9JqqYrK-pnlnrq7rV7vXM4x3MMMtp8Ke1xEQNx7p93H59u6gEQo0mmJEcSTA1fmOizC93ye9WmTNnxa3atRxthFa8tp4DcHWgmK_mwuN8BJs_oQZ4K2Mjm8RYUGRt0xPMGiZm3mkJZ9zFyFl892u945hvC03uoV1CrcY-JUmC0gBw81krYqW-JqDP_YOVZJ2_dMoknOrQ2_tAs77qWdQCTH3Evb_Z2RvqquTDD-q2bRjB9rLBipnZL-PJrz0QQ-dNRYQBO6XES7PY_TPu436rqnfbyLe02h8rcl1IVu7PmDK4MDf_CIP7gqsecPBv7gwB8c-LOMrk6O-0dnkT9VIyoSlg0jJTuGijyRVEMobJgmeUwLoQkVRAlTcCETCXaaCQ5fyhUXQoEXKAwnJkmpIStoqqxKvYqwkVJIAjZAQVRKMhiAq9gQXlBuw-Z0Da24p3MzcKVTbvxjW_-uYwPNNizbRNMGZqreArdvKLdrwD4AKwtS8g
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+activated+charcoal+on+digoxin+and+digitoxin+clearance&rft.jtitle=Drug+intelligence+%26+clinical+pharmacy&rft.au=Park%2C+G+D&rft.au=Goldberg%2C+M+J&rft.au=Spector%2C+R&rft.au=Johnson%2C+G+F&rft.date=1985-12-01&rft.issn=0012-6578&rft.volume=19&rft.issue=12&rft.spage=937&rft_id=info:doi/10.1177%2F106002808501901216&rft_id=info%3Apmid%2F4085353&rft_id=info%3Apmid%2F4085353&rft.externalDocID=4085353
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-6578&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-6578&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-6578&client=summon